Teladoc (TDOC) Stock May Be 41% Undervalued On Cash Flow Strength

Teladoc Health stock has lost about 94.1% over the past five years, yet the current price around US$8.92 screens as cheap on both a Discounted Cash Flow (DCF) intrinsic value estimate and standard valuation multiples, creating a clear gap between past returns and what the current checks suggest.

• The roughly 94.1% decline over five years points to a company where expectations have been reset and where sentiment has been heavily compressed.
• Future revenue growth and cash flow from Teladoc Health's virtual care platform can support the intrinsic value case. However, any setback in converting that activity into durable, positive free cash flow may limit how much of the apparent discount closes.
• Across the broader set of valuation checks, Teladoc Health looks inexpensive, scoring 5 out of 6 on Simply Wall St's value framework, which points to a broad-based view of the stock as undervalued.

The stock's next move may depend on whether Teladoc Health can turn this valuation discount into a more sustained recovery in shareholder returns.

Teladoc Health delivered 4.0% returns over the last year. See how this stacks up to the rest of the Healthcare Services industry.

Is Teladoc Health a Bargain on Cash Flow?

The Discounted Cash Flow (DCF) method values Teladoc Health by projecting future cash the business could generate for shareholders and discounting it back to today. On this basis, the model uses latest twelve month free cash flow of about $148 million and applies a growing cash flow profile over time. This reflects expectations that the virtual care business continues to produce positive free cash flow.

Those cash flow projections translate into an estimated intrinsic value of about $15 per share, compared with the recent share price near $8.92. That gap implies the stock trades at roughly a 41.3% discount to the DCF estimate, suggesting the market price is not fully reflecting the cash flow potential embedded in Teladoc Health’s current operations.

On this cash flow view, Teladoc Health stock screens as undervalued relative to its estimated intrinsic worth.

Our Discounted Cash Flow (DCF) analysis suggests Teladoc Health is undervalued by 41.3%. Track this in your watchlist or portfolio, or discover 47 more high quality undervalued stocks.

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Teladoc Health.

Does Teladoc Health Look Undervalued on Sales?

For Teladoc Health, the P/S ratio is a useful yardstick because the business is still being judged heavily on revenue from its virtual care platform rather than on accounting earnings.

Teladoc Health currently trades on a P/S of about 0.6x, which is well below both the Healthcare Services industry average of roughly 2.6x and a peer average near 4.8x. The Simply Wall St fair P/S ratio for Teladoc Health is estimated at about 2.0x, indicating that the current multiple is below the level that might be expected given its size, sector and risk profile.

This wide gap between the present sales multiple and the fair ratio indicates a market that is pricing Teladoc Health cautiously relative to its revenue base.

On the P/S measure, Teladoc Health stock currently appears undervalued compared with both its industry and the modelled fair multiple.

See what the numbers say about this price — find out in our valuation breakdown.

The Teladoc Health Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Teladoc Health pick up where this valuation puzzle leaves off by spelling out which combinations of future growth, margins and earnings would make the stock worth materially more or less than today’s price, and they sit on the company’s Community page. Each narrative presents Teladoc Health's estimated fair value as a thesis about the business that you can revisit over time to see how the underlying assumptions hold up.

Community views on Teladoc Health sit far apart, with one side focused on cash flow support and the other on execution and margin risks.

Bull case: 41% undervalued

"Despite the market narrative of a failing pandemic stock, Teladoc’s underlying financial engine tells a radically different story…"

Read the full Bull Case to see why Teladoc Health could be undervalued

Bear case: 21% overvalued

"The transition from higher-margin cash pay users to lower-margin insurance-based revenue in the BetterHelp segment is expected to depress overall gross margins…"

Read the full Bear Case to see why Teladoc Health could be overvalued

Do you think there's more to the story for Teladoc Health? Head over to our Community to see what others are saying!

The Bottom Line

Teladoc Health screens as undervalued on both its Discounted Cash Flow (DCF) intrinsic value estimate and its revenue multiple, and the broader valuation checks back up that picture rather than contradict it. For you as an investor, the real hinge is whether Teladoc Health can steadily translate its virtual care scale into durable, positive free cash flow and healthier margins. If that happens, today’s discount may look like an opportunity, but if execution stalls, the current pricing could instead reflect a market that remains cautious for good reason.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com